Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843277 | 1.00 | CNR2 (0.33) | CNR2CNR1CRHR1ROCK2HPGDS | |
| SCHEMBL21458303 | 1.00 | CNR2 (0.33) | CNR2CNR1CRHR1ROCK2HPGDS | |
| SCHEMBL22927027 | 0.93 | CNR2 (0.35) | CNR2CNR1ROCK2HPGDSP2RX3 | |
| SCHEMBL21481971 | 0.91 | CRHR1 (0.40) | CNR2CNR1CRHR1HPGDSCHRM4 | |
| SCHEMBL21458168 | 0.88 | ROCK2 (0.34) | CNR2CNR1ROCK2HPGDSP2RX3 | |
| SCHEMBL21481946 | 0.88 | ROCK2 (0.34) | CNR2CNR1ROCK2HPGDSP2RX3 | |
| SCHEMBL21485598 | 0.87 | NTRK1 (0.37) | CNR2CNR1ROCK2PTGER4 | |
| SCHEMBL21458273 | 0.87 | NTRK1 (0.37) | CNR2CNR1ROCK2PTGER4 | |
| SCHEMBL21458242 | 0.87 | PTGER4 (0.40) | CNR2CNR1CRHR1ROCK2HPGDS | |
| SCHEMBL30843267 | 0.87 | PTGER4 (0.40) | CNR2CNR1CRHR1ROCK2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885CRHR1 87/4885 |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885CRHR1 87/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885CRHR1 87/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885CRHR1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.